Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Tisotumab-vedotin (Primary)
- Indications Bladder cancer; Cervical cancer; Endometrial cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors Genmab
- 22 Nov 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
- 22 Nov 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
- 21 Nov 2017 This trail has been completed in Denmark